Skip to main content

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.

Publication ,  Conference
Crawford, J; Wolff, DA; Culakova, E; Poniewierski, MS; Selby, C; Dale, DC; Lyman, GH
Published in: Blood
November 16, 2004

Introduction: Myelosuppression represents the major dose-limiting toxicity of cancer chemotherapy. This prospective, nationwide study was undertaken to better define risk of neutropenia and its complications and to develop risk models for selecting patients for appropriate supportive care.Methods: More than 3,500 patients initiating a new chemotherapy regimen have been prospectively registered at 137 randomly selected practice sites. Major disease sites include breast, lung, colorectal, ovary and lymphoma. Primary outcomes include severe neutropenia (SN; absolute neutrophil count nadir <500) and febrile neutropenia (FN) (fever/infection and nadir <1000) by cycle of treatment and overall.Results: This analysis is based on the first 2,361 patients treated to date including 924 (39%) age ≥65. Severe neutropenia was documented in 28% and FN in 16% across all cancer categories. The proportion of patients with ANC <500 over the first four cycles of treatment include: colorectal (8%); lung (18%); ovary (23%); lymphoma (27%) and breast (37%). Likewise, the proportion of patients with FN during the first four cycles include: colorectal (7%); lung (11%); ovary (13%); lymphoma (18%) and breast (20%). As shown in the table, approximately half of the initial episodes of ANC <500 and FN over four cycles of treatment occurred in cycle 1.Neutropenic Events By Cycle (% Patients) Primary Outcome Cycle 1 (N=2361) Cycle 2 (N=2032) Cycle 3 (N=1724) Cycle 4 (N=1246) Total (N=2361) Any SN 16 11 10 11 48 1st Cycle SN 16 6 4 2 28 Any FN 8 6 5 1 20 1st Cycle FN 8 4 3 1 16The proportion of initial episodes of severe neutropenia that occur in cycle 1 include: colorectal (67%); lung (59%); ovary (44%); lymphoma (62%) and breast (70%). Likewise, the proportion of initial episodes of FN occurring in cycle 1 include: colorectal (53%); lung (60%); ovary (57%); lymphoma (56%) and breast (58%).Conclusions: Rates of severe and febrile neutropenia vary with tumor type. The initial episode of severe or febrile neutropenia is most likely to occur during the first cycle of chemotherapy across all major cancer types.

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 16, 2004

Volume

104

Issue

11

Start / End Page

2210 / 2210

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crawford, J., Wolff, D. A., Culakova, E., Poniewierski, M. S., Selby, C., Dale, D. C., & Lyman, G. H. (2004). First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study. In Blood (Vol. 104, pp. 2210–2210). American Society of Hematology. https://doi.org/10.1182/blood.v104.11.2210.2210
Crawford, Jeffrey, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, Caleb Selby, David C. Dale, and Gary H. Lyman. “First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.” In Blood, 104:2210–2210. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.2210.2210.
Crawford J, Wolff DA, Culakova E, Poniewierski MS, Selby C, Dale DC, et al. First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study. In: Blood. American Society of Hematology; 2004. p. 2210–2210.
Crawford, Jeffrey, et al. “First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.Blood, vol. 104, no. 11, American Society of Hematology, 2004, pp. 2210–2210. Crossref, doi:10.1182/blood.v104.11.2210.2210.
Crawford J, Wolff DA, Culakova E, Poniewierski MS, Selby C, Dale DC, Lyman GH. First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study. Blood. American Society of Hematology; 2004. p. 2210–2210.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 16, 2004

Volume

104

Issue

11

Start / End Page

2210 / 2210

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology